Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia&#39;s Landmark Tumor-Agnostic Immunotherapy Reimbursement.

Yervoy (ipilimumab) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Keytruda (pembrolizumab) - Merck (MSD)

Nivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement. (PubMed, J Clin Oncol) - Oct 2, 2026 - No abstract available
Journal • Reimbursement • US reimbursement • Oncology

http://www.ncbi.nlm.nih.gov/pubmed/42821835

Razelle Kurzrock; Vivek Subbiah

Oct 2, 2026